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ABSTRACT 
Background: The primary physiologic function of platelets is to facilitate hemo- 
stasis by aggregation. Volatile anesthetics have been reported to decrease plate- 
let aggregation i vivo and in vitro. 
Objective: The aim of this study was to investigate the hematologic effects 
of the anesthetics isoflurane, sevoflurane, and desflurane on hemoglobin (Hb), 
hematocrit (Hct), platelet count, activated partial thromboplastin time (aPTT), 
prothrombin time (PT), international normalized ratio (INR), and platelet aggre- 
gation after minor surgery. 
Methods: Patients aged 20 to 60 years who were scheduled to undergo 
minor surgery and American Society of Anesthesiologists physical status P1 
or P2 (healthy or mild systemic disease) were randomized to 1 of 3 groups: 
1 minimum alveolar concentration (MAC) of isoflurane, sevoflurane, or desflu- 
rane. None of the patients received premedication. Anesthesia was induced using 
IV thiopental 5to 6 mg/kg, fentanyl 1 to 2 IJg/kg, and vecuronium 0.1 mg/kg, and 
maintained with 1 MAC of isoflurane, sevoflurane, or desflurane in 66% nitrous 
oxide and 33% oxygen. Vecuronium 0.03 mg/kg was given when necessary for 
muscle relaxation. All patients were monitored throughout surgery; isotonic 
saline was given at a rate of 5 mL/kg • h. Hematologic studies were performed 
preoperatively, 15 minutes after intubation, and 1 hour after the end of surgery. 
Platelet aggregation tests were performed in a laboratory using a platelet function 
analyzer (PFA), collagen/epinephrine PFA test cartridges, collagen/adenosine 
diphosphate PFA test cartridges, and PFA trigger solution. 
Results: This prospective, randomized, single-blind, in vivo study was con- 
ducted at Gevher Nesibe Teaching Hospital, Erciyes University, Kayseri, Turkey. 
Thirty patients (15 men, 15 women) were randomized to the 3 treatment groups 
(each, n = 10). Hb, Hct, platelet count, aPT% P% and INR were statistically 
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similar between all 3 groups. The measured parameters were not significantly 
different between the isoflurane and desflurane groups at any time point. 
However, in the sevoflurane group, mean (SD) platelet aggregation was signifi- 
cantly delayed 15 minutes after intubation and 1 hour after surgery compared 
with the preoperative values (collagen/epinephrine, 81.70 [9.85] seconds vs 
196.20 [27.84] seconds and 115.40 [25.80] seconds; both, P< 0.05). 
Conclusions: In this study of the effects of isoflurane, sevoflurane, and des- 
flurane in patients undergoing minor surgery, clinically relevant antithrombotic 
effects were observed 15 minutes after intubation with all 3 drugs, although the 
effects in patients receiving sevoflurane were significantly greater compared 
with those in patients receiving isoflurane and desflurane. The antithrombotic 
effects of isoflurane and desflurane were not continued at 1 hour after surgery; 
however, the inhibitory effects of sevoflurane on platelet function were contin- 
ued at 1 hour after surgery but were significantly decreased from levels found 
at 15 minutes after intubation. (Curr Ther Res Clin Exp. 2005;66:375-384) Copy- 
right © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Volatile anesthetics might decrease platelet aggregability in vivo and in vitro./-21 
Effects of halothane on platelet function were first found by Ueda, 3 who showed 
that halothane inhibited adenosine diphosphate (ADP)-induced platelet aggre- 
gation using aggregometry in canine blood. Based on a MEDLINE search (key 
terms: halothane, isoflurane, sevoflurane, desflurane, and platelet function; years: 
1960-2004), numerous tudies have shown the effects of halothane, isoflurane, 
and sevoflurane on platelet function3 -2T However, we found only 3 studies 14-16 
of the effects of desflurane on platelet function and bleeding time, and the results 
of these studies differed. 
Because the effects of desflurane on platelet function are unclear, we assessed 
the hematologic effects of isoflurane, sevoflurane, and desflurane on hemoglobin 
(Hb), hematocrit (Hct), platelet count, activated partial thromboplastin time 
(aPTT), prothrombin time (PT), international normalized ratio (INR), and platelet 
aggregation after minor surgery. 
PATIENTS AND METHODS 
This prospective, randomized, single-blind, in vivo study was conducted at Gevher 
Nesibe Teaching Hospital, Erciyes University, Kayseri, Turkey. Patients aged 20 to 
60 years who were scheduled to undergo a minor elective surgical procedure (eg, 
knee arthroscopy, hand surgery) and American Society of Anesthesiologists phys- 
ical status P1 or P2 (healthy or mild systemic disease) were eligible for the study. 
All patients provided written informed consent o participate. Approval for the 
study protocol was obtained from the ethics committee at the university. 
376 
N. Bozdogan et al. 
Patients were excluded from the study for the following reasons: use of war- 
farin, herbal supplements, or NSAIDs, including aspirin; presence of a severe 
systemic disease, hypertension, diabetes mellitus, renal failure, gastrointestinal 
symptoms, or bleeding diathesis; or a history of allergy or sensitivity or contra- 
indications to anesthetics. Patients were also excluded if they were uncon- 
scious, pregnant, or breast-feeding. 
Before surgery, patients were randomized, in a 1:1 ratio using a computer- 
generated list of random numbers, to 1 of 3 treatment groups: 1 minimum alve- 
olar concentration (MAC) of isoflurane, sevoflurane, or desflurane. None of the 
patients were administered premedication. Anesthesia was induced with IV 
thiopental 5 to 6 mg/kg, fentanyl 1 to 2 IJg/kg, and vecuronium 0.1 mg/kg, and 
was maintained with 1 MAC of isoflurane, sevoflurane, or desflurane in 66% 
nitrous oxide and 33% oxygen. Fifteen minutes after endotracheal intubation, 
when end-tidal concentrations reached 1 MAC, the surgical procedure was 
started. When necessary, vecuronium 0.03 mg/kg was administered to maintain 
muscle relaxation. 
Ventilation was performed to preserve nd-tidal carbon dioxide concentra- 
tion on expiration (ETCO2) of 30 to 35 mm Hg. Patients were monitored through- 
out surgery and administered isotonic saline at 5 mL/kg • h during surgery. None 
of the patients were given a colloid infusion or a blood transfusion. 
During surgery, electrocardiography and noninvasive automatic measure- 
ment of heart rate and blood pressure (measured inthe contralateral rm) were 
performed, ETCO 2 and body temperature (AS/3, Datex-Engstrom, Inc., Helsinki, 
Finland) were measured, and arterial oxyhemoglobin saturation was monitored 
using pulse oximetry. 
One hour before surgery, an 18-G cannula was inserted into a peripheral 
vein to collect blood specimens; that cannula was not used for IV fluid therapy. 
The specimens were collected preoperatively, 15minutes after intubation, and 
1 hour after the end of surgery. Blood specimens were collected into vacuum 
tubes (Vacutainer, Beckton, Dickinson and Company, Franklin Lakes, New 
Jersey) containing EDTA for measurement of Hb, Hct, and platelet count; 1.8-mL 
blood specimens were collected into vacuum tubes containing 3.2% sodium cit- 
rate for determination f aPTT, PT, and INR; and 3.6-mL blood specimens were 
collected into vacuum tubes containing 3.2% sodium citrate for determination 
of platelet aggregation. To prevent blood coagulation, the tubes of specimens 
were turned upside down 4 or 5 times. The tubes were sent to the Hematology 
and Coagulation Laboratories, Kayseri, Turkey, within 2 hours of collection. The 
tests were performed by hematologists blinded to treatment assignment. 
Platelet aggregation tests were performed in the laboratory using a platelet 
function analyzer (PFA-100, Dade Behring Inc., Marburg, Germany), collagen/ 
epinephrine (Col/Epi) PFA test cartridges, collagen/ADP (Col/ADP) PFA test car- 
tridges, and PFA trigger solution (Dade Behring Inc.). The cartridges were stored 
at 2°C to 8°C and dwelled at room temperature for 15 minutes before testing. The 
PFA-100 device was adjusted to take measurements at 37°C. 
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The 2 test cartridges, Col/Epi and Col/ADP, were placed in the cassette of 
PFA-100 simultaneously, and an 800-1JL blood specimen was infused through the small 
opening in the test cartridges, using a pipette. Trigger solution containing 11 mL 
of isotonic saline was spread on the membrane to solubilize Col/Epi or Col/ADP, 
and blood levels were measured. Coagulated specimens were not to be used, and 
results found to have system errors were not to be included in the analysis. 
Statistical Anal~is 
Statistical analyses were carried out using Statistica version 4.3 (Statsoft 
Inc., Tulsa, Oklahoma). Variables are expressed as mean (SD). Because the 
Kolmogorov-Smirnov test revealed a normal distribution of the data, we used 
analysis of variance (ANOVA). For prestudy power and sample size calculation, 
assuming a = 0.05 and a power of 80%, ~8 patients would be required in each 
group to detect a 20% increase in the estimated mean baseline Col/Epi and 
Col/ADP values of 80 (15) seconds (PS Power and Sample Size Calculations ver- 
sion 2.1.30, Microsoft Corporation, Redmond, Washington). To compensate for 
nonevaluable patients, we planned to enroll 10 patients per group. One-way 
ANOVA and the post hoc Tukey HSD test, when appropriate, were used for inter- 
group analyses, and ANOVA for repeated measures was used for intragroup 
analyses. P < 0.05 was considered statistically significant. 
RESULTS 
The study comprised 30 patients (15 men, 15 women) (10 per treatment group). 
No significant differences indemographic and clinical characteristics, duration of 
surgery, or hemodynamic properties were found between the 3 groups (Table I). 
The effects of isoflurane, sevoflurane, and desflurane on Hb, Hct, platelet 
count, aPTT, PT, INR, and collagen before and after minor surgery are shown in 
Table II. No significant differences in Hb, Hct, or platelet count were found be- 
tween the groups. No significant between-group differences in aPTT, PT, or INR 
measured at all 3 time points or in preoperative Col/Epi and Col/ADP levels were 
found. However, Col/Epi and Col/ADP values 15 minutes after intubation and 
1 hour after surgery were significantly higher in the sevoflurane group compared 
with those in the isoflurane and desflurane groups (all, P < 0.05). lntragroup 
analyses howed that Col/Epi and Col/ADP levels significantly increased 15 min- 
utes after intubation in all 3 groups (all, P < 0.05), and increased 1hour after sur- 
gery in the sevoflurane group (P < 0.05). Significantly higher levels were observed 
in both Col/Epi and Col/ADP only in the sevoflurane group 1 hour after surgery 
(both, P < 0.05). However, Col/Epi and Col/ADP levels obtained at 1 hour after sur- 
gery were significantly lower compared with those obtained at 15 minutes after 
intubation in all 3 groups (all, P < 0.05). 
Two specimens were excluded from analysis in the isoflurane group because 
of coagulation, and none of the specimens were excluded from the sevoflurane 
or desflurane groups. 
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Table I. Baseline demographic and clinical characteristics and hemodynamic proper- 
ties of study patients (N = 30).* Values are presented as mean (SD) unless 
otherwise specified. 
Isoflurane Sevoflurane Desflurane 
Characteristic (n = 10) (n = 10) (n = 10) 
Age, y 41.50 (9.94) 37.90 (9.82) 37.20 (7.26) 
Weight, kg 73.80 (11.12) 75.70 (10.59) 70.90 (8.81) 
Sex, no. 
Female 5 5 5 
Male 5 5 5 
Duration of surgery, rain 71.40 (13.45) 79.10 (15.61) 67.70 (11.49) 
Thiopental, mg 428.70 (47.21) 440.20 (52.31) 425.30 (50.92) 
Vecuronium, mg 9.40 (1.73) 10.10 (1.1 O) 9.00 (1.05) 
SAP, mm Hg 138.60 (20.03) 135.00 (11.78) 129.50 (11.44) 
DAP, mm Hg 82.10 (5.89) 80.70 (6.76) 78.70 (7.02) 
HR, bpm 82.10 (8.22) 83.40 (6.50) 75.50 (8.27) 
SpO2, o/6 97.10 (1.1 9) 98.30 (1.49) 97.04 (0.94) 
SAP = systolic arterial pressure; DAP = diastolic arterial pressure; HR 
hemoglobin saturation as monitored using pulse oximetry. 
*No significant intergroup differences were found. 
= heart rate; SpO 2 = arterial oxy- 
DISCUSSION 
lsoflurane, sevoflurane, and desflurane did not significantly affect Hb, Hct, 
platelet count, aPTT, PT, or INR. Based on Col/Epi and Col/ADP levels, signifi- 
cantly increased platelet aggregation was observed with all 3 treatments at 
15 minutes after intubation compared with preoperative l vels. Platelet aggre- 
gation was significantly greater with sevoflurane compared with isoflurane and 
desflurane 15 minutes after intubation and 1 hour after surgery. The effects of 
desflurane and isoflurane were not significantly different from baseline 1 hour 
after surgery. Desflurane and isoflurane had similar effects on Col/Epi and 
Col/ADP. 
The literature search revealed only 3 studies of the effects of desflurane on 
platelet function and bleeding time. 14-1G Frohlich et a114 and Mielke et a115 found 
that 0.5 MAC of desflurane did not affect platelet function. Berlet et al 1G 
reported that desflurane had differential effects, by impairing platelet aggrega- 
tion while not affecting a-degranulation, on various aspects of platelet activa- 
tion that are similar to those of halothane in healthy blood donors. 
Such conflicting findings of studies of the effects of inhalational nesthetics 
on platelet aggregation might be ascribed to the fact that measurement meth- 
ods, induction agents, MACs, and test tubes were found to vary in both in vivo 
and in vitro studies. 3-21 The PFA-100 device best simulates injuries in the vessel 
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Table II. Effects of isoflurane (n = 8), sevoflurane (n = 10), and desflurane (n = 10) on 
hemoglobin (Hb), hematocrit (Hct), platelet count, activated partial throm- 
boplastin time (aPTT), prothrombin time (PT), international normalized 
ratio (INR), and collagen before and after minor surgery. Values are pre- 
sented as mean (SD). 
Before Surgery 15 Minutes After 1 HourAfter 
Parameter/Study Drug (Baseline) Intubation Surgery 
Hb, g/dL 
Isoflurane 13.99 (I .36) 1 3.24 (I .29) 13.58 (I .45) 
Sevoflurane 13.96 (1.40) 12.85 (2.01) 13.61 (1.43) 
Desflurane 13.72 (I .42) 1 3.27 (I .I 8) 13.66 (I .20) 
Hct, % 
Isoflurane 41.41 (4.07) 39.05 (4.25) 40.42 (4.29) 
Sevoflurane 41.99 (4.06) 38.74 (5.60) 40.89 (4.45) 
Desflurane 49.47 (4.29) 39.38 (3.64) 40.40 (3.96) 
Platelet count, cells x 103/IJL 
Isoflurane 276.10 (35.08) 266.60 (42.82) 286.10 (42.21) 
Sevoflurane 282.10 (552.92) 250.00 (44.09) 274.60 (53.80) 
Desflurane 272.80 (396.14) 260.20 (37.57) 274.20 (33.94) 
a PTi-, s 
Isoflurane 32.85 (4.28) 34.15 (4.19) 31.41 (4.29) 
Sevoflurane 35.08 (3.07) 37.56 (3.71) 34.01 (5.1 3) 
Desflurane 31.20 (3.54) 33.21 (4.12) 31.34 (3.45) 
PT, s 
Isoflurane 12.14 (0.73) 1 2.68 (0.85) 12.88 (0.77) 
Sevoflurane 12.15 (0.91) 1 2.64 (I .02) 12.10 (0.86) 
Desflurane 12.31 (0.84) 1 2.71 (0.97) 12.52 (0.79) 
INR 
Isoflurane 1.02 (0.05) 1.05 (0.07) 1.07 (0.06) 
Sevoflurane 1.01 (0.09) 1.07 (0.11 ) 1.03 (0.07) 
Desflurane 1.04 (0.10) 1.06 (0.10) 1.03 (0.03) 
Collagen/epinephrine, s 
Isoflurane 85.70 (9.11) 119.40 (19.11) 101.60 (13.73)* 
Sevoflurane 81.70 (9.85) 196.20 (27.84) t~ 115.40 (25.80) *t~ 
Desflurane 82.30 (7.57) 100.60 (6.16) t 94.50 (7.93)* 
CollagenlADP, s 
Isoflurane 81.20 (7.37) 99.5 (I 2.25) t 85.60 (6.43)* 
Sevoflurane 76.90 (7.23) 202.80 (37.80) t* 100.30 (15.97) *t~ 
Desflurane 78.80 (7.37) 93.60 (5.12) t 88.30 (7.81)* 
ADP = adenosine diphosphate. 
*P < 0.0S versus 15 minutes after intubation. 
tp < 0.05 versus baseline. 
~P < 0.0S between groups. 
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walls in in vitro conditions. Flow cytometry, agrometry, spectrophotometry, 
thromboelastography, and Sonoclot analyses have all been used in previous 
studies; however, it has been reported that these devices are not as sensitive as 
the PFA-100 device. 3-n,17-24 
The failure to demonstrate inhibitory effects on platelets has been mainly 
attributed to inhalational nesthetics being volatilized in the tubes while blood 
specimens are stored before aggregation tests are performed, n In an in vitro 
study, De La Cruz et al 2s reported that vacuum test tubes prevented volatiliza- 
tion of anesthetic agents. We used the PFA-100 device, the sensitivity of which 
has been reported to be 90% to 95%, to measure platelet aggregation. 2s,27 We 
also used vacuum test tubes to prevent volatilization of anesthetics and to 
avoid their contact with room air. 
Antiaggregation effects of inhalation anesthetics have been investigated in
many in vitro studies. 3,4,s,~-1°,21 We investigated the effects of ADP and collagen 
on platelet aggregation, and statistically significant differences from baseline 
were found with 1 MAC of isoflurane and desflurane on platelet aggregation 
15 minutes after intubation. These effects were probably not clinically significant, 
and they had resolved at 1 hour after surgery. During surgery, platelet activa- 
tion causes the release of vasoactive substances (eg, serotonin, thromboxane). 
Platelets become temporarily hypoaggregable during surgery; after surgery 
they become hyperaggregable. 5 Using agrometry, Lichtenfeld et al s assessed 
the effects of volatile agents on platelet aggregation and reported that not only 
anesthetics, but also major surgical stresses, influenced platelet function. For 
this reason, we collected blood specimens 15 minutes after intubation (ie, before 
surgery) to avoid the effects of surgical stimulation on platelet function. 
Although some investigators have reported that sevoflurane invarious MACs 
had inhibitory effects on platelet aggregation, 1°-14,21,24,2L28 others found that 
sevoflurane did not have such effects, n,15,2T It may be that the methods and 
MACs used varied between the studies. Dordoni et a112 studied the in vivo and 
in vitro effects of thiopental, propofol, and sevoflurane on platelet function dur- 
ing thyroid surgery and found that the combination of thiopental, fentanyl, and 
sevoflurane significantly reduced collagen-induced aggregation by the end of 
induction, whereas ADP-induced aggregation and thromboxane generation were 
unaffected. The combination of propofol, fentanyl, and sevoflurane had no 
effect on platelets. They also found that thiopental inhibited platelets in vitro in 
a dose-dependent manner, whereas fentanyl or propofol did not. The present 
study used the same thiopental/fentanyl induction protocol in the isoflurane, 
sevoflurane, and desflurane groups. In contrast to Dordoni et al, 12 we found that 
sevoflurane had considerable effects on platelets. Our results agree with those 
of Horn et al, 13 who studied the in vitro effect of 0.5 MAC of sevoflurane on 
platelet antigen expression and function in healthy volunteers, using flow cy- 
tometry, thromboelastography, andPFA measurements. They found that sevo- 
flurane inhibited agonist-induced glycoprotein lib/Ilia activation and surface 
expression on platelets in whole blood with subanesthetic concentrations in 
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vitro. Hirakata et a121 found that isoflurane (0.28-0.84 mmol/L) did not influ- 
ence the aggregation induced by ADP and epinephrine, but that sevoflurane 
(0.13-0.91 mmol/L) and halothane (0.49-1.25 mmol/L) inhibited secondary 
platelet aggregation i duced by ADP and epinephrine without affecting primary 
platelet aggregation. They explained that sevoflurane xerted this inhibitory 
effect via suppression of cyclooxygenase activity and thromboxane A 2 (TxA2) 
formation and that sevoflurane showed its antiaggregation effect, which is 
reversible, without changing TxA 2 receptor binding affinity. The authors also 
claimed that sevoflurane had a stronger inhibitory effect on secondary aggrega- 
tion compared with halothane. 
Dogan et al u found that sevoflurane had a considerable inhibitory effect on 
platelet aggregation i  patients who underwent minor elective surgery, and a 
residual effect was seen 1 hour after surgery. Similarly, we did not find a sig- 
nificant between-group difference in Hb, Hct, platelet count, PT, aPTT, INR, 
or sevoflurane-inhibited platelet aggregation, as reported in previous stud- 
ies. 1°'11'13-15'21 One MAC of isoflurane, sevoflurane, and desflurane inhibited 
ADP- and epinephrine-induced platelet aggregation 15 minutes after intubation, 
but this inhibitory effect was higher in patients administered sevoflurane and 
continued at 1 hour after surgery. Berlet et a116 studied the in vitro effects of des- 
flurane and halothane on platelet activation in healthy volunteer blood donors, 
using ADP and collagen to stimulate platelets. Using Born aggregometry and flow 
cytometry to measure platelet response, the authors reported that desflurane 
had differential effects on various aspects of platelet activation that were similar 
to those of halothane. These reports consistently support our findings. 
Yokubol et al 1° reported that sevoflurane suppressed cyclooxygenase activ- 
ity and thus decreased TxA 2 formation, which in turn increased bleeding time 
in patients undergoing minor elective surgery. They also noted that despite the 
increase in bleeding time and inhibition of platelet aggregation, the amount of 
blood lost was too small to require blood transfusion in any patient. We agree 
with Yokubol et al 1° that the inhibitory effect of sevoflurane does not cause clin- 
ically important blood loss and that this loss is not important in patients with 
homeostasis. On the other hand, the inhibitory effects may be useful in that 
they decrease the risk for thrombogenic complications. 5 
We suggest hat anesthetists should be aware of the potential impairment of 
the coagulation profile by anesthetic agents in surgery that poses a risk for severe 
hemorrhage and in patients with blood diathesis and thrombosis disorders. 
CONCLUSIONS 
In this study of the effects of isoflurane, sevoflurane, and desflurane in patients 
undergoing minor surgery, clinically relevant antithrombotic effects were ob- 
served 15 minutes after intubation with all 3 drugs, although the effects in 
patients receiving sevoflurane were significantly greater compared with those 
in patients receiving isoflurane and desflurane. The antithrombotic effects of 
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isof lurane and desf lurane were not  cont inued at 1 hour  after surgery;  however,  
the  inh ib i tory  effects of sevof lurane on platelet funct ion were cont inued at 
1 hour  after surgery  but  were signif icantly decreased  from levels found at 15 min- 
utes after intubation. 
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